ED
NGM

Exane Derivatives’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Exane Derivatives’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$154 Sell
12
-2,277
-99% -$31.5K ﹤0.01% 696
2022
Q1 		$34.9K Buy
2,289
+184
+9% +$2.87K 0.01% 608
2021
Q4 		$37.3K Buy
2,105
+2,012
+2,163% +$38.6K 0.01% 535
2021
Q3 		$1.96K Sell
93
-1,095
-92% -$24.1K ﹤0.01% 805
2021
Q2 		$25.9K Sell
1,188
-5,351
-82% -$125K 0.01% 689
2021
Q1 		$190K Buy
6,539
+720
+12% +$20.2K 0.05% 307
2020
Q4 		$176K Buy
+5,819
New +$127K 0.05% 327

Other funds holding NGM

CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Exane Derivatives's NGM Position: Q2 2022 in Review

Exane Derivatives reduced its NGM Biopharmaceuticals, Inc. Common Stock (NGM) stake by 99% in Q2 2022, selling an estimated $31.5K and leaving 12 shares worth $154. The position accounts for ﹤0.01% of the portfolio, ranked #696.

Exane Derivatives first reported a position in NGM in Q4 2020 and has held it in 7 quarters since. The position peaked at $190K in Q1 2021. 123 funds tracked by Wall St. Rank hold NGM as of Q2 2022.

  • Exane Derivatives held 12 shares of NGM Biopharmaceuticals, Inc. Common Stock worth $154 as of Q2 2022.
  • Exane Derivatives sold 2,277 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $31.5K.
  • NGM Biopharmaceuticals, Inc. Common Stock made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #696 holding.
  • Exane Derivatives first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2020 and has held it in 7 quarters since.
  • Exane Derivatives's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $190K in Q1 2021.
  • 123 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.